Phage-Therapy Providers
Dedicated to the ecology and evolutionary biology of the parasites of unicellular organisms (UOPs)
|
Bacteriophage Ecology Group Phage-Therapy Providers |
|
Dedicated to the ecology and evolutionary biology of the parasites of unicellular organisms (UOPs) | ||
| © Stephen T. Abedon | ||
| contents | phage ecology group | top of page | ||
| © Phage et al. | last updated on Sunday, April 23, 2000 |
The Bacteriophage Ecology Group will be taking a stab at providing a phage-therapy providers list. These would be individuals or groups who wish to advertise their use of this antibacterial technique. The Bacteriophage Ecology Group does not at this point make any claim as to the validity or efficacy of assertions made by listed individuals. If you wish to list yourself or your group on this page, then please send an e-mail supplying your address, phone number, e-mail address, homepage if one exists, affiliation if any, and a short description of how you or your group employ phages either therapeutically or preventively. The Bacteriophage Ecology Group reserves the right to reject any application deemed by the members as inappropriate. Individuals actively involved in research into the clinical employment of phage therapy may want to consider joining the bacteriophage ecology group. See also the phage-therapy bibliography and the phage-therapy links list.
| name (home page links) |
phone/fax | address | |
|---|---|---|---|
| Exponential Biotherapies, Inc. (potential "wholesale" phage provider) |
carltonebi @erols.com |
516-883-6883 516-883-6903 |
Exponential Biotherapies, Inc., 150 Main Street, Port Washington, NY 11050 |
| Exponential Biotherapies, Inc. ("EBI") is a development-stage biotechnology company with phages about to enter into clinical trials. The company's major targets at this time are the highly drug-resistant hospital strains of Enterococcus faecium, Staphylococcus aureus (staph), and Pseudomonas aeruginosa. Additional pathogens are on the "back burner", and the company is interested in hearing from scientists as well as clinicians who have interests in the pathogens both in the human sector and the agricultural sector. ¶ The laboratories are located in Rockville, Maryland, near the National Institutes of Health (NIH), with which the company has had an active collaboration. U.S. and foreign patents have issued on the company's method of overcoming the rapid clearance to which phages are subjected (by the spleen and other filtering organs of the body). This rapid filtering drastically lowers the numbers of phages administered that will be available to reach and kill the infecting bacteria. The company's early results were published in April 1996 issue of the Proceedings of the National Academy of Sciences-US, and a favorable guest editorial by Nobel laureate Dr. Joshua Lederberg accompanies the article. | |||
| Victor Krylov (potential "wholesale" phage provider) |
krylov @genetika.ru |
--- | The State Institute for Genetics and Selection of Industrial microorganisms, 1-st Dorozhnii proezd, 1, Moscow 113545, RUSSIA (alternative e-mail addresses include: kry38vik.yahoo.com or krylov@vniigenetika.msk.su) |
| We have studied Pseudomonas aeruginosa bacteriophages for a number of years using electron microscopy and DNA homology data for classification purposes. We have now some perspective ideas to elaborate and enlarge the collection of the phages and enhance lytic properties of the existing phages to use them in clinical conditions to prevent cross-infection of patients with pathogenic P. aeruginosa strains. We need very modest financial support to develop the ideas for clinical application. | |||
contents | phage-therapy providers | top of page
Contact Steve Abedon (microdude+@osu.edu) with suggestions, criticisms,
comments, or anything else that might help make this a better site.